In this issue of Annals of Surgical Oncology, Utuama et al. use the National Cancer Database (NCD... more In this issue of Annals of Surgical Oncology, Utuama et al. use the National Cancer Database (NCDB) in a propensity score-matched model to investigate whether neoadjuvant chemotherapy impacts survival for patients with intrahepatic cholangiocarcinoma (ICC). Overall, only 8.4% of the cohort underwent neoadjuvant chemotherapy for resectable ICC. Utuama et al. found that for patients with stage II and III ICC, survival was improved with neoadjuvant chemotherapy compared with an upfront surgical approach (hazard ratio [HR] 0.58, 95% confidence interval [CI] 0.37–0.91; p = 0.02). No survival advantage was seen when the stage I patients were included in both the unadjusted (HR 0.92, 95% CI 0.64–1.31; p = 0.66) and propensity score-matched analysis (HR 0.94, 95% CI 0.62–1.40; p = 0.72). This study suggests there may be a significant role for the use of neoadjuvant therapy in stage II and III ICC patients to improve survival. Currently, the National Comprehensive Cancer Network (NCCN) guide...
In this issue of Annals of Surgical Oncology, Utuama et al. use the National Cancer Database (NCD... more In this issue of Annals of Surgical Oncology, Utuama et al. use the National Cancer Database (NCDB) in a propensity score-matched model to investigate whether neoadjuvant chemotherapy impacts survival for patients with intrahepatic cholangiocarcinoma (ICC). Overall, only 8.4% of the cohort underwent neoadjuvant chemotherapy for resectable ICC. Utuama et al. found that for patients with stage II and III ICC, survival was improved with neoadjuvant chemotherapy compared with an upfront surgical approach (hazard ratio [HR] 0.58, 95% confidence interval [CI] 0.37–0.91; p = 0.02). No survival advantage was seen when the stage I patients were included in both the unadjusted (HR 0.92, 95% CI 0.64–1.31; p = 0.66) and propensity score-matched analysis (HR 0.94, 95% CI 0.62–1.40; p = 0.72). This study suggests there may be a significant role for the use of neoadjuvant therapy in stage II and III ICC patients to improve survival. Currently, the National Comprehensive Cancer Network (NCCN) guide...
Uploads
Papers by Sara Masry